Harvard Bioscience (HBIO) stock price, revenue, and financials

Harvard Bioscience market cap is $292.6 m, and annual revenue was $102.1 m in FY 2020

$292.6 M

HBIO Mkt cap, 31-Dec-2021

$27 M

Harvard Bioscience Revenue Q1, 2021
Harvard Bioscience Gross profit (Q1, 2021)15.4 M
Harvard Bioscience Gross profit margin (Q1, 2021), %57.2%
Harvard Bioscience Net income (Q1, 2021)-669 K
Harvard Bioscience EBIT (Q1, 2021)-239 K
Harvard Bioscience Cash, 31-Mar-20215.8 M
Harvard Bioscience EV339.6 M
Get notified regarding key financial metrics and revenue changes at Harvard BioscienceLearn more
Banner background

Harvard Bioscience Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

105.2m108.7m108.7m104.5m101.9m120.8m116.2m102.1m

Revenue growth, %

3%0%(4%)

Cost of goods sold

59.3m59.9m56.1m54.3m57.6m51.9m44.1m

Gross profit

49.3m48.7m48.4m47.6m63.2m64.3m58.0m

Gross profit Margin, %

45%45%46%47%52%55%57%

Sales and marketing expense

20.6m20.5m21.0m24.4m23.3m19.9m

R&D expense

6.4m5.4m5.6m11.0m10.7m8.7m

General and administrative expense

19.8m21.0m18.6m21.4m22.8m23.5m

Operating expense total

50.4m51.4m47.7m62.2m63.9m57.8m

Depreciation and amortization

2.8m2.7m2.4m5.4m5.7m

EBIT

1.5m6.6m(1.7m)(3.0m)(101.0k)984.0k377.0k221.0k

EBIT margin, %

1%6%(2%)(3%)0%1%0%0%

Interest expense

955.0k990.0k1.9m81.0k2.0m9.0m5.4m4.8m

Interest income

43.0k74.0k

Pre tax profit

435.0k4.4m(3.6m)(3.1m)(2.1m)(8.0m)(5.5m)(7.3m)

Income tax expense

15.4m1.2m(1.2m)(3.7m)(815.0k)518.0k

Net Income

(1.8m)2.4m(19.0m)(4.3m)(865.0k)(2.9m)(4.7m)(7.8m)

Quarterly

USDQ2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

26.1m25.1m25.4m25.8m28.8m25.7m27.0m26.1m25.0m24.2m25.2m25.1m26.8m31.5m28.6m28.2m29.6m27.4m23.8m23.3m24.0m27.0m

Cost of goods sold

14.0m13.8m14.0m14.3m16.2m14.0m14.0m14.5m13.3m12.7m13.9m13.4m13.5m16.2m12.8m12.0m13.6m12.4m10.8m9.5m10.5m11.6m

Gross profit

12.1m11.3m11.4m11.5m12.6m11.7m12.9m11.7m11.7m11.5m11.3m11.6m13.3m15.4m15.8m16.2m16.0m15.0m13.0m13.9m13.5m15.4m

Gross profit Margin, %

46%45%45%45%44%46%48%45%47%48%45%46%50%49%55%57%54%55%55%59%56%57%

Sales and marketing expense

4.6m4.4m4.1m5.2m5.1m5.0m5.1m5.1m5.0m5.0m5.0m5.1m5.6m6.3m6.0m6.3m5.8m5.3m5.6m4.3m4.6m5.4m

R&D expense

2.0m1.9m1.1m1.7m1.7m1.4m1.4m1.5m1.3m1.3m1.3m1.5m2.4m2.8m2.8m2.7m2.8m2.6m2.5m1.9m1.9m2.5m

General and administrative expense

5.6m5.3m4.1m4.8m4.9m5.0m5.9m5.2m4.8m5.2m4.4m4.5m5.4m5.3m4.7m5.6m4.8m6.6m6.8m5.7m5.4m6.3m

Operating expense total

12.9m12.4m10.0m12.6m12.5m12.5m13.2m12.5m12.5m12.1m11.3m11.8m14.5m15.7m14.9m16.1m15.7m16.3m16.3m13.3m13.3m15.7m

Depreciation and amortization

676.0k600.0k618.0k793.0k678.0k666.0k680.0k690.0k729.0k599.0k604.0k622.0k1.1m1.4m1.5m1.4m1.4m1.4m1.4m1.5m1.5m

EBIT

(772.0k)(1.1m)1.4m(1.1m)99.0k(775.0k)(221.0k)(840.0k)(813.0k)(639.0k)1.0k(136.0k)(1.3m)(382.0k)890.0k34.0k228.0k(1.4m)(3.3m)556.0k182.0k(239.0k)

EBIT margin, %

(3%)(4%)6%(4%)0%(3%)(1%)(3%)(3%)(3%)0%(1%)(5%)(1%)3%0%1%(5%)(14%)2%1%(1%)

Interest expense

245.0k276.0k469.0k614.0k526.0k321.0k222.0k73.0k67.0k404.0k463.0k274.0k4.0m1.5m1.8m1.8m1.4m1.3m1.3m1.2m1.2m411.0k

Pre tax profit

(1.1m)(1.4m)956.0k(1.8m)(427.0k)(1.1m)(443.0k)(767.0k)(880.0k)(1.0m)(462.0k)(410.0k)(5.2m)(1.9m)(908.0k)(1.8m)(1.1m)(2.7m)(4.5m)(868.0k)(1.4m)(684.0k)

Income tax expense

(808.0k)(433.0k)323.0k(363.0k)(776.0k)(249.0k)193.0k(54.0k)758.0k23.0k(81.0k)7.0k605.0k(369.0k)(652.0k)576.0k(885.0k)(54.0k)55.0k713.0k(300.0k)(15.0k)

Net Income

(186.0k)(983.0k)1.7m633.0k(1.4m)349.0k(847.0k)(636.0k)(713.0k)(1.6m)(1.1m)(381.0k)(417.0k)(4.1m)(1.5m)(256.0k)(2.4m)(247.0k)(2.6m)(4.5m)(1.6m)(1.1m)(669.0k)

Harvard Bioscience Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.7m5.7m8.2m8.3m8.3m

Accounts Receivable

17.5m16.2m21.5m20.7m17.8m

Prepaid Expenses

3.9m4.2m3.1m

Inventories

22.3m21.4m25.1m22.1m22.3m

Current Assets

50.5m47.5m57.8m53.6m51.7m

PP&E

5.9m4.1m5.9m4.8m4.0m

Goodwill

40.4m40.0m57.3m57.4m58.6m

Total Assets

120.2m109.4m168.6m164.9m156.3m

Accounts Payable

8.8m4.6b5.4m7.4m5.3m6.0m

Short-term debt

2.5m11.9m9.3m3.8m

Current Liabilities

19.4m14.0m21.5m25.3m21.1m

Long-term debt

16.5m9.0m58.8m55.1m53.8m

Total Debt

18.9m11.7m2.0m64.5m57.6m

Total Liabilities

42.6m28.5m85.9m83.2m79.6m

Common Stock

416.0k419.0k436.0k438.0k444.0k

Preferred Stock

Additional Paid-in Capital

211.5m218.8m226.4m229.2m232.4m

Retained Earnings

(111.7m)(117.0m)(119.9m)(124.6m)(132.4m)

Total Equity

77.6m80.9m82.7m81.7m76.7m

Debt to Equity Ratio

0.2 x0.1 x0 x0.8 x

Debt to Assets Ratio

0.2 x0.1 x0 x0.4 x

Financial Leverage

1.5 x1.4 x2 x2 x2 x

Quarterly

USDQ2, 2013Q3, 2013Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

34.1m36.9m26.7m8.0m7.4m6.1m4.2m3.6m5.3m4.6m4.7m5.8m6.0m5.6m6.7m5.0m4.9m6.8m5.9m2.6m2.8m5.8m

Accounts Receivable

13.8m13.4m14.3m16.0m18.5m15.6m18.0m16.3m15.1m15.5m16.0m15.3m19.0m19.6m17.9m18.8m18.4m17.1m15.4m14.7m13.9m17.1m

Prepaid Expenses

5.0m4.1m4.1m4.8m4.9m5.1m4.3m4.6m4.5m4.8m4.8m4.9m3.0m2.8m4.2m3.2m3.9m4.5m

Inventories

18.3m18.0m18.1m22.1m23.1m23.0m22.2m22.2m21.2m20.3m20.4m21.4m27.9m25.6m25.7m26.6m25.3m23.9m23.1m23.2m22.7m22.7m

Current Assets

72.8m73.9m65.0m52.8m56.5m52.3m48.7m46.8m46.2m45.1m45.8m47.4m55.8m53.7m54.5m53.6m52.5m52.3m48.2m44.1m43.5m49.2m

PP&E

4.4m4.6m4.1m5.6m5.8m5.9m5.7m5.6m5.3m4.3m4.3m4.3m5.8m5.5m5.4m5.6m5.4m5.2m4.5m4.2m4.3m3.7m

Goodwill

35.6m36.3m35.9m40.3m41.1m40.9m40.5m39.7m39.6m38.4m39.3m39.8m56.2m55.7m55.8m57.4m57.2m56.6m56.8m57.0m57.6m58.2m

Total Assets

146.0m148.3m136.1m134.1m138.6m133.6m117.9m114.1m112.2m107.4m108.9m110.7m170.9m165.1m165.0m171.3m166.2m162.8m156.3m150.7m149.6m151.2m

Accounts Payable

4.9m4.7m5.1m7.2m8.8m6.3m6.2m6.6m6.1m5.8m5.6m5.6m7.4m7.7m5.4m7.3m6.0m5.3m6.6m6.6m6.0m6.4m

Short-term debt

21.0m21.9m(24.1m)(24.6m)(25.6m)(26.2m)(27.5m)(27.8m)(28.3m)(29.0m)(30.1m)(31.1m)(25.5m)(26.1m)(27.7m)5.1m5.1m5.0m4.0m

Current Liabilities

13.3m13.5m15.6m19.8m21.2m17.3m15.9m14.9m14.4m14.1m13.2m13.9m22.3m22.2m19.3m24.1m20.9m21.7m23.5m22.7m21.2m20.7m

Long-term debt

21.3m20.5m18.2m16.9m15.7m15.2m14.8m13.8m12.7m10.9m10.4m9.7m61.6m59.8m59.2m63.2m61.1m60.1m54.1m48.8m48.4m48.8m

Total Debt

42.2m23.5m23.2m(7.7m)20.7m20.2m17.1m16.2m15.0m13.7m13.2m12.4m63.0m1.6m1.8m2.2m2.4m2.6m59.3m53.9m53.4m52.8m

Total Liabilities

40.7m40.5m39.4m43.6m43.8m39.3m39.7m37.4m36.3m34.7m33.6m33.8m91.7m88.0m84.1m91.0m85.9m85.7m80.3m74.6m72.4m74.1m

Common Stock

375.0k382.0k395.0k401.0k415.0k416.0k416.0k417.0k417.0k418.0k418.0k418.0k422.0k427.0k435.0k436.0k436.0k436.0k438.0k438.0k438.0k448.0k

Preferred Stock

Additional Paid-in Capital

199.8m200.8m205.4m207.6m209.8m210.7m212.1m213.1m214.1m215.8m216.7m217.6m220.0m221.9m225.5m226.5m227.2m228.2m229.7m230.7m231.1m234.8m

Retained Earnings

(77.4m)(78.3m)(92.7m)(94.1m)(93.7m)(94.6m)(112.4m)(113.1m)(114.7m)(117.2m)(117.5m)(118.0m)(121.0m)(122.5m)(122.8m)(122.3m)(122.5m)(125.1m)(129.1m)(130.7m)(131.8m)(133.1m)

Total Equity

105.4m107.8m96.8m90.5m94.8m94.3m78.2m76.7m75.9m72.7m75.2m76.9m79.3m77.0m81.0m80.3m80.3m77.1m76.0m76.1m77.2m77.1m

Debt to Equity Ratio

0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.8 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0.2 x0.2 x0.1 x0.2 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.4 x0 x0 x0 x0 x0 x

Financial Leverage

1.4 x1.4 x1.4 x1.5 x1.5 x1.4 x1.5 x1.5 x1.5 x1.5 x1.4 x1.4 x2.2 x2.1 x2 x2.1 x2.1 x2.1 x2.1 x2 x1.9 x2 x

Harvard Bioscience Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.8m)2.4m(19.0m)(4.3m)(865.0k)(2.9m)(4.7m)(7.8m)

Depreciation and Amortization

3.9m3.8m4.6m4.3m3.8m2.4m7.7m1.9m

Accounts Receivable

(735.0k)(1.3m)566.0k196.0k(2.8m)468.0k3.1m

Inventories

(3.1m)(1.2m)1.2m(548.0k)2.6m3.3m413.0k

Accounts Payable

(41.0k)1.1m2.6m(2.4m)(918.0k)1.6m(2.0m)511.0k

Cash From Operating Activities

4.1m4.4m705.0k5.4m1.1m2.9m8.0m9.3m

Purchases of PP&E

(1.6m)(2.0m)(4.5m)(986.0k)(1.2m)(1.2m)

Cash From Investing Activities

171.0k(13.5m)(7.5m)(62.0k)(917.0k)(53.8m)(229.0k)(1.4m)

Long-term Borrowings

(2.7m)(5.5m)(8.3m)(9.0m)(4.7m)(20.2m)(11.7m)(66.9m)

Cash From Financing Activities

(1.2m)(540.0k)(4.9m)(1.8m)53.1m(7.6m)(8.0m)

Net Change in Cash

(7.4m)(1.1m)137.0k2.4m162.0k(18.0k)

Interest Paid

892.0k997.0k854.0k620.0k686.0k5.0m5.5m4.9m

Income Taxes Paid

1.5m843.0k963.0k928.0k(13.0k)98.0k374.0k416.0k

Quarterly

USDQ2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(92.0k)(1.1m)1.7m2.4m(1.4m)(1.1m)(1.9m)(636.0k)(1.3m)(3.0m)(1.1m)(1.4m)(1.9m)(4.1m)(5.5m)(5.8m)(2.4m)(2.6m)(5.2m)(4.5m)(6.1m)(7.2m)(669.0k)

Depreciation and Amortization

662.0k2.9m1.8m2.8m1.2m2.2m3.3m1.1m2.2m3.3m905.0k1.9m2.8m495.0k1.1m1.5m2.0m3.8m5.8m1.9m3.9m5.8m1.9m

Accounts Receivable

265.0k948.0k(294.0k)(557.0k)115.0k(2.1m)754.0k(463.0k)959.0k2.1m410.0k125.0k1.0m149.0k(993.0k)918.0k2.7m2.7m3.8m5.1m5.9m6.8m584.0k

Inventories

(932.0k)(227.0k)(1.3m)(2.6m)(758.0k)(1.2m)(1.3m)211.0k(95.0k)735.0k(300.0k)31.0k(608.0k)799.0k2.1m2.1m(1.4m)(209.0k)635.0k(1.4m)(1.4m)(511.0k)(602.0k)

Accounts Payable

287.0k(15.0k)349.0k446.0k790.0k2.5m35.0k(2.7m)(2.5m)(2.8m)(320.0k)(703.0k)(786.0k)1.3m1.8m(442.0k)(118.0k)(1.4m)(2.1m)1.3m1.3m665.0k(245.0k)

Cash From Operating Activities

1.4m2.8m2.5m3.1m(497.0k)(981.0k)(1.1m)(726.0k)216.0k3.7m(610.0k)(135.0k)2.0m448.0k1.7m291.0k2.0m2.7m5.8m2.9m5.2m6.8m1.0m

Purchases of PP&E

585.0k(744.0k)(4.5m)(4.5m)(4.5m)(198.0k)(677.0k)(493.0k)(634.0k)(891.0k)(143.0k)(423.0k)(778.0k)(241.0k)(524.0k)(1.1m)(151.0k)

Cash From Investing Activities

(639.0k)629.0k(666.0k)(1.1m)(5.6m)(6.2m)(6.8m)(205.0k)(412.0k)(954.0k)228.0k(476.0k)(716.0k)(52.2m)(52.9m)(53.2m)(152.0k)588.0k227.0k(241.0k)(524.0k)(1.1m)(301.0k)

Long-term Borrowings

(750.0k)(1.5m)(2.5m)(3.7m)(2.8m)(4.8m)(6.1m)(2.6m)(4.6m)(6.7m)(1.1m)(2.6m)(3.5m)(14.0m)(17.2m)(19.9m)(4.6m)(8.5m)(11.1m)(4.8m)(16.4m)(20.3m)(4.5m)

Cash From Financing Activities

13.3m12.5m(1.5m)(135.0k)832.0k1.0m621.0k(1.7m)(2.6m)(3.7m)(268.0k)(629.0k)(1.4m)51.2m50.7m53.4m(5.0m)(6.5m)(7.2m)(5.1m)(10.4m)(11.3m)(3.1m)

Net Change in Cash

13.4m16.3m963.0k(6.1m)(6.7m)(8.0m)(2.6m)(3.1m)(1.4m)(997.0k)(872.0k)240.0k258.0k(109.0k)928.0k(3.1m)(3.2m)(1.3m)(2.5m)(5.7m)(5.5m)(2.5m)

Interest Paid

272.0k534.0k458.0k757.0k175.0k427.0k625.0k194.0k312.0k468.0k164.0k347.0k503.0k944.0k2.4m3.5m927.0k2.9m4.2m1.2m2.5m3.8m458.0k

Income Taxes Paid

1.0m1.2m688.0k451.0k350.0k312.0k625.0k171.0k452.0k725.0k333.0k(196.0k)(96.0k)(489.0k)(208.0k)(170.0k)94.0k299.0k411.0k110.0k98.0k410.0k(113.0k)

Harvard Bioscience Ratios

USDQ2, 2013

Financial Leverage

1.4 x

Harvard Bioscience Employee Rating

2.731 votes
Culture & Values
2.6
Work/Life Balance
3.6
Senior Management
2.4
Salary & Benefits
3.1
Career Opportunities
2.7
Source